1 no longer available, 1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Progressive Metastatic Castrate Resistant Prostate Cancer: new trials by email Literature Review of Progressive Metastatic Castrate Resistant Prostate Cancer trials Research Report on Progressive Metastatic Castrate Resistant Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) Tulmimetostat DL1 QD, Tulmimetostat DL2 QD, Tulmimetostat DL3 QD - Progressive Metastatic Castrate Resistant Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 188 | 2025-10-15 | 2026-10-09 |
| Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib Trametinib 2 mg - Progressive Metastatic Castrate Resistant Prostate Cancer | No longer available | Jonsson Comprehensive Cancer Center | 2019-01-16 |
Standard of Care (1) · trametinib (1)
Jonsson Comprehensive Cancer Center (1) · Novartis Pharmaceuticals (1)
Australia (1) · Canada (1) · China (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Malaysia (1) · Mexico (1) · Poland (1) · Singapore (1) · Spain (1) · United Kingdom (1) · United States (1)
2025 (1)